The patent covers the use of this therapeutic for treating dyskinesia associated with L-DOPA therapy in Parkinson’s disease.
"This recent patent award will provide robust protection for MLR-1019 through 2034, and represents a significant milestone towards Melior’s second major development program," said Andrew Reaume PhD, President and CEO of Melior Discovery.
MLR-1019 is a repositioned small molecule drug candidate that Melior is developing for treating Parkinson’s disease.
Extensive animal model data indicates that MLR-1019 will have the unique property of attenuating patients’ dyskinesia while simultaneously improving the therapeutic benefit of L-DOPA.
Melior Discovery and Melior Pharmaceuticals, its sister company, are leaders in pharmaceutical drug repositioning using the unique theraTRACE platform comprised of multiplexed in vivo disease models.
Melior is using these capabilities to build an internal pipeline of development candidates and also partners with pharmaceutical and biopharmaceutical companies to apply the theraTRACE platform and its in-depth in vivo pharmacology expertise to their development candidates. Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA.